Bioventus (Nasdaq:BVS) announced today that it successfully completed the divestiture of its Advanced Rehabilitation business. The Durham, North Carolina-based company divested the unit to Accelmed Partners. Accelmed, a private equity (PE) firm, focuses on acquiring and growing commercial-stage healthtech companies. Bioventus initially announced the deal to divest Advanced Rehabilitation on Oct. 1, 2024. The company […]
Bioventus
Bioventus names Medtronic, J&J veteran as CEO
Bioventus (Nasdaq:BVS) announced that it appointed Robert Claypoole as its new president and CEO, effective Jan. 10, 2024. Claypoole succeeds Anthony Bihl, who served as interim CEO and board director since April 2023. Bihl took over in the interim role after Ken Reali stepped down for unknown reasons after three years in the corner office. […]
Bioventus completes wound business divestiture
Bioventus (Nasdaq:BVS) announced today that it successfully completed the divestiture of its wound business to LifeNet Health. Earlier this month, the Durham, North Carolina-based company announced an agreement to divest the business to LifeNet. The sale includes Bioventus’ skin substitutes, TheraSkin and TheraGenesis. The transaction includes a total cash consideration of $85 million. That features […]
Bioventus divests wound business to LifeNet Health
Bioventus (Nasdaq:BVS) announced today that it signed a definitive agreement to sell its wound business to LifeNet Health. Durham, North Carolina-based Bioventus’ sale includes its skin substitutes, TheraSkin and TheraGenesis. The transaction includes a total cash consideration of $85 million. That features $35 million at close, $5 million deferred 18 months and $45 million in […]
Bioventus CEO Ken Reali steps down
Bioventus (Nasdaq:BVS) announced today that Ken Reali stepped down as the company’s CEO and as a member of its board. Durham, North Carolina-based Bioventus said its board initiated a comprehensive search process to identify a permanent CEO. Until it finds one, the board appointed Anthony Bihl as interim CEO, effective immediately. Bihl has more than […]
Bioventus completes $315M CartiHeal acquisition
Bioventus (Nasdaq:BVS) announced today that it completed its previously announced $315 million acquisition of CartiHeal. Durham, North Carolina-based Bioventus announced in April that it agreed to acquire CartiHeal in a deal worth at least $315 million. Just last month, the company amended the agreement for the deal to defer a large amount of payments. The amendment […]
Bioventus restructures $315M CartiHeal acquisition
Bioventus (Nasdaq:BVS) amended the agreement for its pending acquisition of CartiHeal to defer a large chunk of payments. Durham, North Carolina-based Bioventus announced in April that it agreed to acquire the orthopedic implant maker in a deal worth at least $315 million. An amendment to the acquisition agreement reduces the closing payment to $50 million […]
Bioventus announces $415M offering
Bioventus (Nasdaq:BVS) announced today that it intends to offer $415 million in aggregate principal amount of senior notes due in 2027. Durham, North Carolina-based Bioventus’ private offering of senior notes will be guaranteed by each of its domestic restricted subsidiaries that guarantee its obligations under its senior secured credit facilities. The company is the creator […]
Bioventus plans to buy CartiHeal for at least $315M to launch knee implant
Bioventus (Nasdaq: BVS) today said it plans to buy CartiHeal following the FDA’s recent premarket approval of the Israel-based medtech developer’s Agili-C implant. Durham, North Carolina-based Bioventus will pay about $315 million to buy the company, excluding the stake already owned by Bioventus after it made a $50 million escrow payment last year. The deal also […]
FDA clears Bioventus’ neXus BoneScalpel Access system
Bioventus (NSDQ:BVS) announced today that it received FDA 510(k) clearance for its neXus BoneScalpel Access handpiece. Durham, North Carolina–based Bioventus said in a news release that the neXus ultrasonic surgical aspirator system — a next-generation integrated ultrasonic surgical platform driven by a proprietary digital algorithm — powers the BoneScalpel Access device. The neXus system combines all […]
Bioventus closes acquisition of Misonix
Bioventus (NSDQ:BVS) announced today that it completed its previously announced acquisition of Misonix for an undisclosed amount. Durham, N.C.-based Bioventus said in a news release that Misonix, a developer of minimally invasive therapeutic ultrasonic technologies and regenerative medicine, has become a wholly-owned subsidiary following the acquisition for cash and common stock. Misonix’s offerings will add […]
